Abstract
The Valsartan Heart Failure Trial (Val-HeFT) established that the angiotensin receptor blocker valsartan is effective for reducing morbidity and slowing the progression of heart failure in patients already taking angiotensin-converting enzymes or beta blockers. In patients not receiving ACE inhibitors, valsartan significantly improves mortality. This review surveys the results from Val-HeFT and makes the point that the concordance between mechanistic data and overall clinical outcomes indicates that neurohormones, echocardiographic data and other parameters might be legitimate surrogate markers in place of clinical outcomes in future heart-failure trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | C25-C28 |
| Journal | European Heart Journal, Supplement |
| Volume | 5 |
| Issue number | C |
| DOIs | |
| State | Published - Apr 2003 |
Keywords
- ACE inhibitor intolerance
- Angiotensin receptor blocker
- Echocardiography
- Neurohormones
- Valsartan